Apoptosis
Apoptosis, also known as programmed cell death, is rigorously controlled process of cell death that leads to phagocytosis of unwanted cell. It is triggered after sufficient cellular damage and activated through extrinsic or intrinsic pathways. The intrinsic pathway is mainly occurs via release of cytochrome c from the mitochondria and regulates mitochondrial outer membrane permeabilization by Bcl-2 family proteins. The extrinsic pathway is induced by ligand binding to death receptor, such as Fas, TNFαR, DR3, DR4, and DR5. Caspases then cleave target proteins and nuclear lamins to promote DNA degradation, resulting apoptotic cells undergo phagocytosis. In addition, p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some Inhibitors of apoptosis proteins (IAPs), such as XIAP/BIRC4 and Bruce/BIRC6, can block casapse activity through direct binding, while other IAPs, such as cIAP1/BIRC2, cIAP2/BIRC3, act as ubiquitin ligases that target caspases for ubiquitin-mediated degradation. Apoptosis is essential for growth, development and aging in multicellular organisms. Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases, including cancer.
-
BA3029 XST-14Summary: XST-14 is a potent, competitive and highly selective inhibitor. -
BA3030 JAK2-IN-7Summary: JAK2-IN-7 is a selective inhibitor. -
BA3032 AQX-435Summary: AQX-435 is a potent activator. -
BA3033 L6H21Summary: L6H21, a derivative, is an orally effective inhibitor of specific myeloid differentiation proteins. -
BA3034 DJ001Summary: DJ001 is a highly specific, selective and non-competitive protein tyrosine phosphatase-σ inhibitor. -
BA3035 CRT0066101Summary: CRT0066101 is a potent inhibitor with oral activity. -
BA3036 KS100Summary: KS100 is a potent inhibitor. -
BA3037 UZH1Summary: UZH1 is the racemate of UZH1a and UZH1b. -
BA3038 PyrazoloacridineSummary: Pyrazoloacridine (NSC366140) has anticancer activity and inhibits topoisomerase 1 and 2 activity (1and2). -
BA3039 TI17Summary: TI17 is an inhibitor of the thyroid hormone receptor-interacting protein Trip13 and has anticancer activity.


